The first two observations of human poisoning involving the recently developed neuroleptic amisulpride are described. In both cases drug determination was per formed using reversed-phase HPLC coupled with diode- array detection. Case 1 was a nonfatal overdosage in which the ingestion of 3.0 g amisulpride induced an attack of seizures, then light coma with agitation, hyperthermia, mydriasis, minimal extrapyramidal features, tachycardia and slight prolongation of the QT interval; the blood con centration of amisulpride was 9.63 μg ml-1. Case 2 was a fatality attributed to amisulpride in which the measured blood concentration was 41.70 μg ml-1. Our results are discussed in the light of data previously reported on the toxicity of substituted benzamides.
Amisulpride, In: The Merck Index (11th ed.), pp. 79-80, Rahway, Merck and Co., 1989.
2.
Clerc G.Etude en double-insu de l'amisulpride (Solian® 50) à différentes posologies chez des malades schizophrènes déficitaires. Semaine des Hôpitaux de Paris1989; 65: 1079-82.
3.
Maubrey MC, Jacquot C., Gonidec J., Guez M., Idee JM & Margarit J.Profil pharmacologique et biochimique de l'amisulpride. Annales de Psychiatrie1988; 3: 284-97.
4.
Sokoloff P., Martres M.P., Redouane K. et al. Behavioral and neurochemical profiles of discriminant benzamide derivatives. Psychiatrie et Psychobiologie1987; 2: 253-63.
5.
Widlocher D. , Allilaire JF, Guerard des Lauriers A. & Lecrubier Y.L'amisulpride, neuroleptique et antidéficitaire. Encéphale1990; 16: 159-63.
6.
Berner P., Küfferle B., Friedmann A., Grünberger J. & Saletu B.Traitement des symptômes déficitaires de la schizophrénie par les neuroleptiques . Encéphale1989;15:457-63
7.
Pichot P. & Boyer P.Essai multicentrique contrôlé en double-insu, amisulpride (Solian® 50) contre fluphénazine à faibles doses dans le traitement du syndrome déficitaire des schizophrénies chroniques. Annales de Psychiatrie1988; 3: 312-20.
8.
Mann K., Bartels M., Bauer H. & Gärtner HJAmisulpride — An open clinical study of a new benzamide in schizophrenic patients. Pharmacopsychiatry1984; 17: 111-5.
9.
Pichot P. & Boyer P.Etude multicentrique contrôlée en double-insu: amisulpride (Solian® 200) versus halopéridol à forte dose dans les états psychotiques aigus. Annales de Psychiatrie1988; 3: 326-32.
10.
Delcker, A. , Schoon ML, Oczkowski B. & Gärtner HJAmisulpride versus haloperidol in treatment of schizophrenic patients. Results of a double-blind study. Pharmacopsychiatry1990; 23: 125-30.
11.
Trillet M., Moreau T., Dalery J., de Villard R. & Aimard G.Traitement de la maladie de Gilles de la Tourette par l'amisulpride. Presse Medicale1990; 19: 175.
12.
Dollfus S., Petit M., Menard JF & Lesieur P.Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function . Journal of Autism and Developmental Disorders1992; 22: 47-60.
13.
Tracqui A., Kintz P., Kreissig P. & Mangin P.Simple and rapid screening procedure for 27 neuroleptics using HPLC/DAD. Journal of Liquid Chromatography1992; 15: 1381-96.
14.
Tracqui A., Kintz P., Jamey C. & Mangin P.Toxicological data in a fatality involving cyamemazine. Journal of Analytical Toxicology1993; 17: 386-8.
15.
Tracqui A., Kintz P., Kreissig P. & Mangin P.A simple and rapid method for toxicological screening of 25 antidepressants in blood or urine using high-performance liquid chromatography with diode-array detection. Annales de Biologie Clinique1992 ; 50: 639-47.
16.
Tracqui A., Kintz, P., Mangin P. & Malicier D.A fatal case of dothiepin self-poisoning. Bulletin of the International Association of Forensic Toxicologists (TIAFT)1992; 22 (3): 28-30.
17.
Dufour A. & Desanti C.Pharmacocinétique et métabolisme de l'amisulpride. Annales de Psychiatrie1988; 3: 298-305.
18.
Moulin A., Truffer D., Rauch-Desanti C., Istin M., Grognet JM & Dufour A.Comparison of HPLC and RIA methods applied to the quantification of amisulpride in human plasma. European Journal of Drug Metabolism and Pharmacokinetics1991; spec. 3: 507-12.
19.
Mokrim R., Brunet C., Cazin M. et al. Amisulpride evaluation by radioreceptor assay. Comparison with HPLC procedure after single administration in the rabbit. Methods and Findings in Experimental and Clinical Pharmacology1993; 15: 41-7.
20.
Bohbot M., Doare L. & Diquet B.Determination of a new benzamide, amisulpride, in human plasma by reversed-phase ion-pair high-performance liquid chromatography. Journal of Chromatography1987; 416: 414-9.
21.
Bogusz M. & Wu M. StandardizedHPLC/DAD system, based on retention indices and spectral library, applicable for systematic toxicological screening. Journal of Analytical Toxicology1991; 15: 188-97.
22.
Logan BK, Stafford DT, Tebbett JR & Moore CMRapid screening for 100 basic drugs and metabolites in urine using cation exchange solid-phase extraction and high-performance liquid chromatography with diode-array detection. Journal of Analytical Toxicology1990; 14: 154-9.
23.
Corvol P., Bisseliches F., Alexandre JM et al. Poussées hypertensives déclenchées par le sulpiride. Semaine des Hôpitaux de Paris1974; 50: 1265-9.
24.
Quinn N. & Marsden CDA double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. Journal ofNeurology, Neurosurgery and Psychiatry1984; 47: 844-7.
25.
Witzel K.Extrapyramidal-motorische Störungen bei Kindern als Nebenwirkung der Therapie mit Neuroleptika und dem neuen Antiemeticum Metoclopramid. Archiv für Kinderheilkunde1968; 177: 277-83.
26.
Indo T. & Ando K.Metoclopramide-induced parkinsonism: clinical characteristics of ten cases . Archives of Neurology1982; 39: 494-6.
27.
Grimes JD, Hasson MH & Preston DNAdverse neurologic effects of metoclopramide . Canadian Medical Association Journal1982 ; 126: 23-5.
28.
Bateman DN, Kahn C. & Davies CSConcentration effect studies with oral metoclopramide. British Journal of Clinical Pharmacology1979; 8: 179-82.
29.
Lavy S., Melamed E. & Penchas S.Tardive dyskinesia associated with metoclopramide. British Medical Journal1978; i: 77-8.
30.
Samie MR, Dannenhoffer MA & Rozek S.Life-threatening tardive dyskinesia caused by metoclopramide. Movement Disorders1987; 2: 125-9.
31.
Reasbeck PG & Hossenbocus A.Death following dystonic reaction to oral metoclopramide. British Journal of Clinical Practice1979; 33: 31-3.
32.
Casey DEMetoclopramide side-effects. Annals of Internal Medicine1983; 98: 673-4.
33.
Pollera C., Cognetti F., Nardi M. & Mazza D.Sudden death after acute dystonic reaction to high-dose metoclopramide. Lancet1984; i: 460-1.
34.
Gaultier M. & Fréjaville JPA propos de 20 surdosages en sulpiride. Journal Européen de Toxicologie et d'Hygiène de l'Environnement1973; 6 (1): 42-4.
35.
Sandyk R.Tardive dyskinesia induced by sulpiride in a patient with hypothyroidism. Clinical Neuropharmacology1986; 9: 100-1.
36.
Beno JM & Nemeth DRDiltiazem and metoclopramide overdose. Journal of Analytical Toxicology1991; 15: 285-7.
37.
Segerberg-Konttinen M., Vuori E., Lukkari I. & Penttilä A.Fatal intoxication by remoxipride. Journal of Forensic Sciences1989; 34: 500-3.
38.
Cramption EL , Glass RC, Marchant B. & Rees JAChemical ionization mass fragmentographic measurement of dothiepin plasma concentrations following a single oral dose in man. Journal of Chromatography1980; 183: 141-8.
39.
Liberatore MA & Robinson DSTorsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy? Journal of Clinical Psychopharmacology1984; 4: 143-6.
40.
Kiriike N., Maeda Y., Nishiwaki S. et al. latrogenic torsades de pointes induced by thioridazine. Biological Psychiatry1987; 22: 99-103.
41.
Kriwisky M. , Perry GY, Tarchitsky D., Gutman Y. & Kison Y.Haloperidol-induced torsades de pointes. Chest1990; 98: 482-4.
42.
Henderson RA , Lane S. & Henry JALife-threatening ventricular arrhythmia (torsades de pointe) after haloperidol overdose. Human and Experimental Toxicology1991; 10: 59-62.
43.
Montaz L., Varache N., Harry P. et al. Torsades de pointes lors d'une intoxication par sultopride. Journal de Toxicologie Clinique et Expérimentale1992; 12: 481-6.
44.
Lande G., Drouin E., Gauthier C. et al. Effet arythmogène du chlorhydrate de sultopride: corrélation clinique et électrophysiologique cellulaire. Annales Françaises d'Anesthésie et de Réanimation1992; 11: 629-35.
45.
Kitano T., Horikomi K., Kamiya J. et al. Studies on general pharmacological properties of sultopride . Pharmacometrics1983; 26: 173-90.
